Therapeutic Effect of Cyclophosphamide cream on cutaneous lymphoma (mycosis fungoides)

Evaluation of the effect of topical Cyclophosphamide compared to topical mometasone in clinical improvement of skin lesions of Cutaneous T cell lymphoma (mycosis fungoides)

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20140212016557N12

Enrollment

Registered

2023-11-27

Start date

2023-12-06

Completion date

Unknown

Last updated

2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cutaneous T cell lymphoma (mycosis fungoides). Mycosis fungoides

Interventions

Intervention 1: Intervention group: topical use of cyclophosphemide 2% cream on the lesion of one side of the body nightly for 3 month by the patient. According to inaccessibility to prepared topical

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: clinically- and histologically-approved cutaneous T cell lymphoma (mycosis fungoides) patients staging of disease 1A,2A,1B patients with active patches and plaques

Exclusion criteria

Exclusion criteria: Allergy to drugs used in the study chemotherapy with cyclophosphemide staging of disease 2B and more pregnancy lactation

Design outcomes

Primary

Measure	Time frame
Composite Assessment of Index Lesion Severity (CAILS). Timepoint: Before intervention, 4 and 8 and 12 weeks after starting intervention. Method of measurement: Hypo/Hyperpigmentation, erythema, scale, plaque elevation according to severity from 0 - 8 and size cm2 grading in 18 states.	—

Secondary

Measure	Time frame
Patients satisfaction. Timepoint: 4 and 8 and 12 weeks after starting intervention. Method of measurement: Greatly decreased = -3 , moderately decreased = -2 , slightly decreased = -1 , no change = 0 , slightly increased = +1, moderately increased = +2 , greatly increased= +3 , Don’t know= photograph was not suitable for proper clinical evaluation.;Physisian global assessment (PGA). Timepoint: Before intervention, 4 and 8 and 12 weeks after starting intervention. Method of measurement: Clear: No signs of MF, but postinflammatory discoloration may be present 1= Almost clear: Only minimal patch/plaque visible, scaling, atrophy, and erythema .2= Mild: Slight patch/plaque visible, scaling, atrophy, and erythema. 3=Moderate: Moderate patch/plaque visible, scaling, atrophy, and erythema.4=Severe: Very marked patch/plaque visible, scaling, atrophy, and erythema.	—

Measure

Time frame

Patients satisfaction. Timepoint: 4 and 8 and 12 weeks after starting intervention. Method of measurement: Greatly decreased = -3 , moderately decreased = -2 , slightly decreased = -1 , no change = 0 , slightly increased = +1, moderately increased = +2 , greatly increased= +3 , Don’t know= photograph was not suitable for proper clinical evaluation.;Physisian global assessment (PGA). Timepoint: Before intervention, 4 and 8 and 12 weeks after starting intervention. Method of measurement: Clear: No signs of MF, but postinflammatory discoloration may be present 1= Almost clear: Only minimal patch/plaque visible, scaling, atrophy, and erythema .2= Mild: Slight patch/plaque visible, scaling, atrophy, and erythema. 3=Moderate: Moderate patch/plaque visible, scaling, atrophy, and erythema.4=Severe: Very marked patch/plaque visible, scaling, atrophy, and erythema.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMozhdeh Sepaskhah

Shiraz University of Medical Sciences

sepaskhah@sums.ac.ir+98 71 3212 5239

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026